Russia 'Unlikely' to Meet Promised 630M Target for COVID Vaccine Doses, Now Partnering with China

Russia, scrambling to meet the ambitious inoculation goals it set when it first authorized its Sputnik V vaccine, will team with Chinese manufacturers to accelerate production of the vaccine in time for its target deadlines.

A London-based science analytics company, Airfinity, told the Associated Press that it estimates Russia agreed to give 630 million doses of its homegrown vaccine to more than 100 countries but has exported only 11.5 million doses so far.

Moscow announced three deals totaling 260 million doses with Chinese vaccine companies in the past few weeks. The doses could reach countries in Latin America, the Middle East and Africa more quickly as a result of the partnership.

The partnership is also a benefit for both Russian and Chinese interests. Rasmus Bech Hansen, founder and CEO of Airfinity, said Russia is "very ambitious and unlikely to meet their full targets."

For more reporting from the Associated Press, see below.

Vaccine Russia
Russia, scrambling to meet the ambitious inoculation goals it set when it first authorized its Sputnik V vaccine, will team with Chinese manufacturers to accelerate production of the vaccine in time for its target deadlines. In this December 10, 2020, file photo, a Russian medical worker prepares a shot of Russia's Sputnik V coronavirus vaccine in Moscow. Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot. Pavel Golovkin, File/AP Photo

Earlier criticism about Russia's vaccine has been largely quieted by data published in the British medical journal The Lancet that said large-scale testing showed it to be safe, with an efficacy rate of 91%.

Yet, experts have questioned whether Russia can fulfill its pledge to countries across the world. While pledging hundreds of millions of doses, it has delivered only a fraction.

Kremlin spokesman Dmitry Peskov has said demand for Sputnik V significantly exceeds Russia's domestic production capacity.

To boost production, the Russian Direct Investment Fund (RDIF), which bankrolled Sputnik V, has signed agreements with multiple drug makers in other countries, such as India, South Korea, Brazil, Serbia, Turkey, Italy and others. There are few indications, however, that manufacturers abroad, except for those in Belarus and Kazakhstan, have made any large amounts of the vaccine so far.

RDIF declined to disclose how many doses are going to other countries. Through April 27, less than 27 million two-dose sets of Sputnik V have been reportedly produced in Russia.

The Russian Direct Investment Fund, which has been in charge of international cooperation for Sputnik V, said in April it would produce 100 million doses in collaboration with Hualan Biological Bacterin Inc., in addition to an earlier deal announced in March for 60 million doses with Shenzhen Yuanxing Gene-tech Co.

The two deals are in addition to a deal announced last November with Tibet Rhodiola Pharmaceutical Holding Co., which had paid $9 million to manufacture and sell the Sputnik V vaccine in China. RDIF said in April the terms of the deal were for 100 million doses with a subsidiary company belonging to Tibet Rhodiola.

In recent years, Chinese vaccine companies have turned from largely making products for use domestically to supplying the global market, with individual firms gaining WHO preapproval for specific vaccines—seen as a seal of quality. With the pandemic, Chinese vaccine companies have exported hundreds of millions of doses abroad.

Chinese vaccine makers have been quick to expand capacity and say they can meet China's domestic need by the end of the year.

"This is an acknowledgment of the Chinese vaccine manufacturers who can produce at volume," said Helen Chen, head of pharmaceuticals LEK Consulting, strategy consultancy firm in Shanghai, in an email.

However, none of the three Chinese companies have yet to start manufacturing Sputnik V.

Tibet Rhodiola started constructing a factory in Shanghai at the end of last year and expects production to start in September, the company said at an annual meeting for investors last month. Tibet Rhodiola Chairman Chen Dalin also said that after the successful technology transfer, they will start with an order of 80 million doses to sell back to Russia. An employee at the company declined to transfer a phone call request to the company's media department for comment.

The timeline for the newest deals are also unclear. Hualan Bio was among the 10 largest vaccines manufacturers in China in 2019. Phone calls to Hualan Bio went unanswered.

A spokeswoman for Shenzhen Yuanxing declined to say when the company will start production but said their order would not be for sale within China. RDIF had said the production will start this month.

In spite of the delays, Russia's vaccine diplomacy has made gains.

From the outset, Russia, the first country to approve a coronavirus vaccine, aimed to distribute it globally. Within weeks of giving Sputnik V regulatory approval, RDIF started actively marketing it abroad, announcing multiple deals to supply the shot to other countries. It is so far winning the "public relations" battle, analysts said in a new report examining Russia and China's vaccine diplomacy from the Economist Intelligence Unit.

"Russia has been able to build stronger diplomatic ties and in areas where it hasn't been able to," before, said Imogen Page-Jarrett, an analyst at EIU. "They have this window of opportunity while the US, E.U. and India are focusing on domestic and the rest of the world is crying out for a vaccine supply."

Newsweek, in partnership with NewsGuard, is dedicated to providing accurate and verifiable vaccine and health information. With NewsGuard's HealthGuard browser extension, users can verify if a website is a trustworthy source of health information. Visit the Newsweek VaxFacts website to learn more and to download the HealthGuard browser extension.